Metabolism of flurazepam, a benzodiazepine, in man and dog
โ Scribed by Morton A. Schwartz; Edward Postma
- Publisher
- John Wiley and Sons
- Year
- 1970
- Tongue
- English
- Weight
- 721 KB
- Volume
- 59
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
โฆ Synopsis
The metabolism of 14C-flurazepam hydrochloride, 7-
hydr0-2H-l,4-benzodiazepin-2-one-5-~~C dihydrochloride, was studied in a dog administered oral and intravenous 2-mg./kg. doses and in two human subjects who each received a 28-mg. oral dose. In both species, evidence was obtained for rapid and essentially complete absorption followed by a rapid elimination of plasma flurazepam. Biotransformation of the drug was rapid and virtually complete in man and dog. Pathways of biotransformation were similar in both species. All the metabolites identified either showed some alteration in the N1-diethylaminoethyl moiety or lacked the Nl-substituent altogether. The major metabolite in the dog was a carboxylic acid, the Nl-acetic acid analog of flurazepam. In man, the analogous alcohol (the Nl-ethanol analog) predominated.
Keyphrases 0 14C-Flurazepam HCI metabolism-humans, dogs 0 Metabolites, flurazepam HCI-isolation, identification 0 Urinary, fecal excretion-14C-flurazepam 0 Plasma le~els-1~C-flurazepam 0 TLC-separation 0 UV spectrophotometry-analysis 0 Scintillometry-analysis
๐ SIMILAR VOLUMES
Intranasal delivery of flurazepam, midazolam, and triazolam was studied in a dog model as a possible alternate route of drug administration for treatment of insomnia. Four beagles received each hypnotic by both intranasal and oral routes on two separate occasions. Plasma concentrations for each hypn
possessing a higher ratio, i.e., thiopental and thiamylal, become concentrated to a higher degree in the body lipids than do barbital or metharbital and might be expected to be ultrashort acting. In considering these solubility data in total, an approximate correlation has been observed between the
The metabolic fate of the benzodiazepine antagonist RO 15-1788 labelled with "C was studied in plasma from human subjects after intravenous administration in connection with positron emission tomography. R o 15-1788 and its metabolites were separated by thin-layer chromatography and the radioactivit